ArticleSubstance abuse2012
A multisite pilot study of extended-release injectable naltrexone treatment for previously opioid-dependent parolees and probationers.
Article in Substance abuse, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 3 syntheses or guidelines pooled it, 58 citations in OpenAlex.
- Pharmacotherapy for opioid addiction in community corrections.International review of psychiatry (Abingdon, England) · 2018Pooled it
- Retention in medication-assisted treatment for opiate dependence: A systematic review.Journal of addictive diseases · 2016Pooled it
- Pharmacological interventions for drug-using offenders.The Cochrane database of systematic reviews · 2015Pooled it
- Extended-release naltrexone for pre-release prisoners: A randomized trial of medical mobile treatment.Contemporary clinical trials · 2017Trial
- Extended-Release Naltrexone to Prevent Opioid Relapse in Criminal Justice Offenders.The New England journal of medicine · 2016Trial
- Extended-release naltrexone to prevent relapse among opioid dependent, criminal justice system involved adults: rationale and design of a randomized controlled effectiveness trial.Contemporary clinical trials · 2015Trial
- Design and methods of a double blind randomized placebo-controlled trial of extended-release naltrexone for HIV-infected, opioid dependent prisoners and jail detainees who are transitioning to the community.Contemporary clinical trials · 2014Trial
- Does mandating offenders to treatment improve completion rates?Journal of substance abuse treatment · 2013Trial
- Design of a pragmatic clinical trial to improve screening and treatment for opioid use disorder in primary care.Contemporary clinical trials · 2023Article
- A national survey of barriers and facilitators to medications for opioid use disorder among legal-involved veterans in the Veterans Health Administration.Substance abuse · 2022Article
- A pilot study of the functionality and clinician acceptance of a clinical decision support tool to improve primary care of opioid use disorder.Addiction science & clinical practice · 2021Article
- Barriers to Medications for Opioid Use Disorder Among Veterans Involved in the Legal System: a Qualitative Study.Journal of general internal medicine · 2020Article
- Combining a Candidate Vaccine for Opioid Use Disorders with Extended-Release Naltrexone Increases Protection against Oxycodone-Induced Behavioral Effects and Toxicity.The Journal of pharmacology and experimental therapeutics · 2020Article
- Medication assisted treatment (MAT) in criminal justice settings as a double-edged sword: balancing novel addiction treatments and voluntary participation.Health & justice · 2020Article
- Perceptions of extended-release naltrexone, methadone, and buprenorphine treatments following release from jail.Addiction science & clinical practice · 2019Article
- The neurobiology of addiction.Annals of the New York Academy of Sciences · 2019Article
- Article
- Treatment Retention Satisfaction, and Therapeutic Progress for Justice-Involved Individuals Referred to Community-Based Medication-Assisted Treatment.Substance use & misuse · 2019Article
- Italian psychiatry.International review of psychiatry (Abingdon, England) · 2018Article
- The daily progress system: A proof of concept pilot study of a recovery support technology tool for outpatient substance abuse treatment.The American journal of drug and alcohol abuse · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 7 institutions in 1 country.
Funding
Abstract
A feasibility study was conducted to pilot test the ability of 5 sites to recruit, treat, and retain opioid-dependent offenders in a trial of extended-release injectable naltrexone (XR-NTX). The participants, 61 previously opioid-dependent individuals under legal supervision in the community, received up to 6 monthly injections of Depotrex brand naltrexone and completed a 6-month follow-up interview. Six-month outcomes showed that those who completed treatment had significantly fewer opioid-positive urines and were less likely to have been incarcerated than those who had not completed treatment. The findings indicate that XR-NTX holds promise as a feasible, effective treatment option for opioid-dependent offenders.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.